Effective Partnering in Conducting Benefit-Risk Patient Preference Studies: Perspectives From a Patient Advocacy Organization, a Pharmaceutical Company, and Academic Stated-Preference Researchers.

Wolka, Anne M; Fairchild, Angelyn O; Reed, Shelby D; Anglin, Greg; Johnson, F Reed; Siegel, Michael; Noel, Rebecca

Wolka, Anne M; Fairchild, Angelyn O; Reed, Shelby D; Anglin, Greg; Johnson, F Reed; Siegel, Michael; Noel, Rebecca.

Afiliación

Wolka AM; 1 Eli Lilly and Company, Indianapolis, IN, USA.
Fairchild AO; 2 Duke Clinical Research Institute, Durham, NC, USA.
Reed SD; 2 Duke Clinical Research Institute, Durham, NC, USA.
Anglin G; 3 Eli Lilly Canada, Inc, Toronto, Ontario, Canada.
Johnson FR; 2 Duke Clinical Research Institute, Durham, NC, USA.
Siegel M; 4 National Psoriasis Foundation, Portland, OR, USA.
Noel R; 1 Eli Lilly and Company, Indianapolis, IN, USA.

Ther Innov Regul Sci ; 52(4): 507-513, 2018 07.

Article en En | MEDLINE | ID: mdl-29714550

Asunto(s)

Medición de Riesgo/métodos; Toma de Decisiones Clínicas; Industria Farmacéutica; Humanos; Colaboración Intersectorial; Defensa del Paciente; Prioridad del Paciente; Investigadores

Palabras clave

academia; benefit-risk; industry; patient advocacy; stated preferences

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Medición de Riesgo Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Ther Innov Regul Sci Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google